Negotiating successful deals is a critical skill for biopharma companies hoping to bring their medical breakthroughs and treatment options to the patients around the globe who need them.  Along the way emerging biotechs need financial and strategic partners to help support thier efforts. While…

After 30-plus years working in Washington DC, it’s clear healthcare decision makers recognize that a patient’s story can add value to a discussion when data cannot. While the value of data is not disputed, the art of patient storytelling is seldom discussed.  I believe this is…

The nomination period is underway for the Buzz of BIO contest at the 2020 CEO & Investor Conference! Winners receive complimentary conference registration, a company presentation in the corresponding track, and opportunities for promotion to industry leaders and investors. …

BIO is continually looking for ways to help its members grow and prosper. This week BIO announced a partnership with Biotech Primer Inc.—a training organization helping professionals understand the science, business, and regulatory processes essential to the biotech industry. Since its start in…

Representing all facets of the patient stakeholder community, participants in BIO’s eighth Patient and Health Advocacy Summit (#BIOSummit19) came together to proclaim: “I am BIO.” But as Dr. Julie Gerberding, executive vice president and chief patent officer at Merck and Co., who acted as the event…

For the FDA, engagement with patients, caregivers and patient advocacy organizations is a vital part of the drug development and review process. However, how that engagement happens can determine how successful it is. This was the key question addressed by the “Practices and Principles: Navigating…

When Mark Dant’s son Ryan was first diagnosed with MPS-I, a rare genetic disorder that leads to organ damage, he had to buy a medical dictionary in order to decipher the words the doctors were saying to him. “I didn’t understand the language of the scientists,” Dant recalled. “The key for every…

Since its inception 17 years ago, the BIO Investor Forum has become the premier event where biotech innovators can find investors and strategic partners to advance their company to the next stage in their business life cycle. Over the past two days, more than 340 private equity and public investors…

As more biotechnology executives begin to focus on strategies to diversify their boards to avoid groupthink and strengthen corporate governance, an emerging consensus is forming that initial public offerings are a key gateway to assembling higher-performing leadership teams. That was the unanimous…

On Tuesday morning at the BIO Investor Forum, leaders from top companies at the forefront of gene therapy innovation assembled to discuss successful approaches, challenges in protein delivery, and the future of expanding this class of medicines. Gene therapies have the potential to increase the…